Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 6;12(7):952.
doi: 10.3390/biom12070952.

Advances in MUC1-Mediated Breast Cancer Immunotherapy

Zhifeng Li  1 , Dazhuang Yang  1 , Ting Guo  2 , Mei Lin  2
Affiliations
Review

Advances in MUC1-Mediated Breast Cancer Immunotherapy

Zhifeng Li et al. Biomolecules. .

Abstract

Breast cancer (BRCA) is the leading cause of death from malignant tumors among women. Fortunately, however, immunotherapy has recently become a prospective BRCA treatment with encouraging achievements and mild safety profiles. Since the overexpression and aberrant glycosylation of MUC1 (human mucin) are closely associated with BRCA, it has become an ideal target for BRCA immunotherapies. In this review, the structure and function of MUC1 are briefly introduced, and the main research achievements in different kinds of MUC1-mediated BRCA immunotherapy are highlighted, from the laboratory to the clinic. Afterward, the future directions of MUC1-mediated BRCA immunotherapy are predicted, addressing, for example, urgent issues in regard to how efficient immunotherapeutic strategies can be generated.

Keywords: MUC1; breast cancer; immunotherapy; mucin; target.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of the MUC1 gene: the MUC1 gene consists of 11 exons (E1 to E11, indicated by green colored boxes), and has 21 isoforms.
Figure 2
Figure 2
The 3D structure of MUC1 (colored by secondary structure), α: alpha spiral, β: beta fold, N: NH2, and C: COOH. The 3D coordinate of the MUC1 structure (PDB ID: 2ACM) was retrieved from the Protein Data Bank (http:/www.rcsb.org/pdb/home.do) (accessed on 2 March 2022). The graphic was created by PyMOL (version 0.99; DeLano Scientific, San Carlos, CA, USA).
Figure 3
Figure 3
Structure and functions of MUC1 in normal tissues and diseased tissues: (A) the structure of MUC1 in normal tissues; (B) the structure of MUC1 in tumor tissues.
Figure 4
Figure 4
Application of MUC1 mediated immunotherapy in BRCA.
See this image and copyright information in PMC

References

    1. Latest Global Cancer Data: Cancer Burden Rises to 19.3 Million New Cases and 10.0 Million Cancer Deaths in 2020. [(accessed on 24 June 2022)]. Available online: https://www.iarc.who.int/fr/news-events/latest-global-cancer-data-cancer...
    1. Burstein H.J., Curigliano G., Thürlimann B., Weber W.P., Poortmans P., Regan M.M., Senn H.J., Winer E.P., Gnant M. Customizing local and systemic therapies for women with early breast cancer: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann. Oncol. 2021;32:1216–1235. doi: 10.1016/j.annonc.2021.06.023. - DOI - PMC - PubMed
    1. Taylor-Papadimitriou J., Burchell J.M., Graham R., Beatson R. Latest developments in MUC1 immunotherapy. Biochem. Soc. Trans. 2018;46:659–668. doi: 10.1042/BST20170400. - DOI - PMC - PubMed
    1. Pourjafar M., Samadi P., Saidijam M. MUC1 antibody-based therapeutics: The promise of cancer immunotherapy. Immunotherapy. 2020;12:1269–1286. doi: 10.2217/imt-2020-0019. - DOI - PubMed
    1. Chen W., Zhang Z., Zhang S., Zhu P., Ko J.K., Yung K.K. MUC1: Structure, Function, and Clinic Application in Epithelial Cancers. Int. J. Mol. Sci. 2021;22:6567. doi: 10.3390/ijms22126567. - DOI - PMC - PubMed

Publication types